Cytotoxicity, accumulation, and efflux of cisplatin and its metabolites in human ovarian carcinoma cells

Toxicology and Applied Pharmacology

Volumn 140, Issue 2, 1996, Pages 211-218

  Shirazi, Farshad H ^a   Molepo, J Matshela ^a   Stewart, David J ^a   Ng, Cheng E ^a   Raaphorst, G Peter ^a   Goel, Rakesh ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DRUG METABOLITE; PLATINUM;

ARTICLE; CELL CULTURE; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOTOXICITY; DNA BINDING; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CARCINOMA; PLASMA;

EID: 0030273389     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1996.0215     Document Type: Article

References (34)

1. Andrews, P. A., Velury, S., Mann, S. C., and Howell, S. B. (1988). cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistance human ovarian carcinoma cells. Cancer Res. 48, 68-73.
2. Andrews, P. A., and Howell, S. B. (1990). Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells 2, 35-43.
3. Binks, S. P., and Dobrota, M. (1990). Kinetics and mechanics of uptake of platinum-based pharmaceutical by the rat small intestine. Biochem. Pharmacol. 40, 281-283.
4. Chabner, B. A. (1990). Cancer; Principles and Practice of Oncology (Third Edition). J. B. Lippincott Company, Philadelphia, PA.
5. Daley-Yates, P. T., and McBrien, D. C. H. (1982). Nephrotoxicity, Assessment and Pathogenesis. p. 356 Wiley, Chichester.
6. Daley-Yates, P. T., and McBrien, D. C. H. (1984). Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumor activity of cisplatin. Biochem. Pharmacol. 33(19), 3063-3070.
7. Daniel, D. V. H., Schilsky, R., Reichert, C. M., Reddick, R. L., Rozencweig, M., Young, R. C., and Muggia, F. M. (1979). Toxic effects of cis-Dichlorodiammineplatinum(II) in Man. Cancer Treat. Rep. 63(9-10), 1527-1531.
8. DeConti, R. C., Toftness, B. R., Lange, R. C., and Creasey, W. A. (1973). Clinical and pharmacologic studies with cis-diamminedichloroplatinum(II) in man. Cancer Res. 33, 1310-1315.
9. De Waal, W. A. J., Maessen, F. J. M. J., and Kraak, J. C. (1987). Analysis of platinum species originating from cis-diamminedichloroplatinum(II) (cisplatin) in human and rat plasma by high-performance liquid chromatography with on-line inductively coupled plasma atomic emission spectrometric detection. J. Chromatogr. 407, 253-272.
10. Disaia, P. J., Sinkouics, J. G., Rutledge, F. N., and Smith, J. P. (1972). Cell-mediated immunity to human malignant cells. Am. J. Obstet. Cyncol. 114, 979-982.
11. Dobrossy, L. (1981). A correlation between cell surface sialyltransferase, sialic acid, and glycosidase activities and the implantability of B16 murine melanoma. Cancer Res. 41, 2262-2266.
12. Duguet, M., Lavenot, C., Harper, F., Mirambeau, G., and De Recondo, A. M. (1983). DNA topoisomerases from rat livers physiological variations. Nucleic Acids Res. 11, 1059-1075.
13. Eichholtz-Wirth, H., and Hietel, B. (1986). The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br. J. Cancer 54, 239-243.
14. Francina, A. (1989). Glycosyltransferase activities in normal and leukaemic amomcytic cells. Clinica. Chimica. Acta 183(3), 301-307.
15. Gately, D. P., and Howell, S. B. (1993). Cellular accumulation of the anticancer agent cisplatin: A review. Br. J. Cancer 67(6), 1170-1176.
16. Goel, R., Andrews, P. A., Pfeifle, C. E., Abramson, I. S., Kirmani, S., and Howell, S. B. (1990). Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy. Eur. J. Cancer 26(1), 21-27.
17. Jekumen, A. P., Hom, D. K., Alcaraz, J. E., Eastman, A., and Howell, S. B. (1994). Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells. Cancer Res. 54, 2680-2687.
18. Jennerwein, M., and Andrews, P. (1994a). Drug accumulation and DNA platination in cells exposed to aquated cisplatin species. Cancer Lett. 81, 215-220.
19. Jennerwein, M., and Andrews, P. (1994b). Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II). Drug Metab. Dispos. 23, 178-184.
20. Johnson, S. W., Swiggard, P. A., Handel, L. M., Jrennan, J. M., Godwin, A. K., Ozols, R. F. L., and Hamilton, T. C. (1994a). Relationship between platinum-DNA adduct formation and removal and cispaltin cytotoxicity in cispaltin-sensitive and -resistant human ovarian cancer cells. Cancer Res. 54, 5911-5916.
21. Johnson, S. W., Perez, R. P., Godwin, A. K., Yeung, A. T., Handel, L. M., Ozols, R. F., and Hamilton, T. C. (1994b). Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol. 47, 689-697.
22. Lee, K. W., and Martin, D. S. (1976). Cis-dichlorodiammineplatinum(II). Aquation equilibria and isotopic exchange of chloride ligands with free chloride and tetrachloro-platinate(II). Inorg. Chim. Acta 17, 105-110.
23. Mann, S. C., Andrews, P. A., and Howell, S. B. (1990). Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother. Pharmacol. 25, 236-240.
24. Melvik, J. E., Dornish, J. M., and Pettersen, E. O. (1992). The binding of cis-dichlorodiammineplatinum(II) to extracellular and intracellular compounds in relation to drug uptake and cytotoxicity in vitro. Br. J. Cancer 66, 260-265.
25. 2) + (X = Cl, OH) with glycine, monohydrogen malonate and chloride. Inorg. Chim. Acta 187, 125-132.
26. Mistry, P., Kelland, L. R., Loh, S. Y., Abel, G., Murrer, B. A., and Harrap, K. R. (1992). Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines. Cancer Res. 52, 6188-6193.
27. Miyahara, T., Ueda, K., Akaboshi, M., Shimada, Y., Imamura, M., and Utsumi, H. (1993). Hyperthermic enhancement of cytotoxicity and increased uptake of cis-diamminedichloroplatinum(II) in cultured human esophageal cancer cells. Jpn. J. Cancer Res. 84(3), 336-40.
28. Ormond, T., Pratt, I., and Ryan, M. P. (1988). Reduced nephrotoxicity in vivo and in vitro of cisplatin-methionine complex. Br. J. Pharmacol. 95, 584P.
29. Pinto, A. L., and Lippard, S. L. (1985). Binding of the antitumour drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim. Biophys. Acta 780, 167-180.
30. Rajesh, P. (1992). Quantification and modulation of cis-diamminedichloroplatinum(II) (cisplatin) binding to DNA and other subcellular components in vivo. Diss. Abs. Inter. 52(8), 4141-B.
31. Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., and Poirier, M. C. (1987). Platinum-DNA adducts in leukocyte DNA correlates with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 84, 5024-5028.
32. Shirazi, S. F. H., Molepo, J. M., Stewart, D. J., Ng, C. E., Raaphorst, G. P., and Goel, R. (1995). The different pharmacologic effects of cisplatin and its metabolites on ovarian cancer cells (OV 2008). Proceedings 7th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (ISPCC) 95, March 1-4, Amsterdam, the Netherlands, #78.
33. Smith, E., and Brock, A. P. (1989). The effect of reduced osmolarity on platinum drug toxicity. Br. J. Cancer 59, 873-875.
34. Terheggen, P. M. A. B., Emondt, J. Y., Floot, B. G. J., Dijkman, R., Schrier, P. I., Engelse, L., and Begg, A. C. (1990). Correlation between cell killing by cis-Diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-Diamminedichloroplatinum(II)-DNA antiserum. Cancer Res. 50, 3556-3561.